Continuing Medical Education -
CME Extended Abstracts Book
TABLE OF CONTENTS

Letter of Invitation by the Congress Chair 5
CME Programme at a Glance 6

WEDNESDAY, OCTOBER 20, 2021

CME 1 - Oncology & Theraonotics Committee: Prostate Cancer - Greatest Hits
Immunohistochemistry and PET Targeting Prostate Specific Membrane Antigen - Now You See Me? Daniela Ferraro (Zurich, Switzerland) 8
PSMA PET in Primary Staging - Ready for Prime Time? The Urologist's Perspective Otto Ettala (Turku, Finland) 9
PSMA PET After Primary Treatment - Anything New? Daniela-Elena Oprea-Lager (Amsterdam, Netherlands) 10
PSMA PET for Castration-Resistant Prostate Cancer - How Far Have We Come? Wolfgang Fendler (Essen, Germany) 11

CME 2 - Physics Committee: AI in Radiomics
Domain Shift, Data Scarcity and (Deep) Domain Adaptation in Medical Imaging Vincent Jaouen (Brest, France) 13
Potential Role of AI and Radiomics in Oncology Martina Sollini (Milan, Italy) 14
Potential Role of AI and Radiomics in Cardiac Imaging Christoph Rischpler (Essen, Germany) 15
What May the Combination of Radiomics and Deep Learning Bring to SPECT and PET of the Brain? Ralph Buchert (Hamburg, Germany) 16

CME 3 - Inflammation & Infection Committee: The Battle Continues - WBC Scan vs FDG PET/CT
Radiolabelled WBC Scintigraphy for Musculoskeletal Infections - Pros and Cons Edel Noriega (Ciudad Real, Spain) 18
FDG-PET for Musculoskeletal Infections - Pros and Cons Zohar Keidar (Haifa, Israel) 19
Radiolabelled WBC Scintigraphy for Cardiovascular Infections - Pros and Cons Francois Rouzet (Paris, France) 20
FDG-PET for Cardiovascular Infections - Pros and Cons Lucia Leccisotti (Rome, Italy) 21

CME 4 - Neuroimaging + Radiopharmacy Committee:
Imaging Neuroinflammation - Everything You Always Wanted to Know, But Were Afraid to Ask
Background of TSPO and Non-TSPO Targets and Their Radiotracers Matthias Brendel (Munich, Germany) 23
Imaging Neuroinflammation with TSPO Ligands - A Critical Reappraisal Bart van Berckel (Amsterdam, Netherlands) 24
Imaging Neuroinflammation - Beyond TSPO Donatienne van Weehaeghe (Leuven, Belgium) 25
<table>
<thead>
<tr>
<th>CME 5 - Cardiovascular + Inflammation &amp; Infection Committee:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammation, Infection and Infiltrative Cardiovascular Diseases - Think Nuclear!</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac Sarcoidosis</strong></td>
<td>Olivier Gheysens (Brussels, Belgium) 27</td>
</tr>
<tr>
<td><strong>The Role of Nuclear Medicine in Cardiac Amyloidosis</strong></td>
<td>Tanja Kero (Uppsala, Sweden) 28</td>
</tr>
<tr>
<td><strong>Endocarditis</strong></td>
<td>Asbjørn Scholtens (Amersfoort, Netherlands) 29</td>
</tr>
<tr>
<td><strong>Vasculitis</strong></td>
<td>Lars Christian Gormsen (Aarhus, Denmark) 30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CME 6 - Oncology &amp; Theranostics Committee: <strong>Quo Vadis PET/MRI?</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methodological Developments</strong></td>
<td>Harald Quick (Essen, Germany) 32</td>
</tr>
<tr>
<td><strong>Where Does PET/MR Enhance PET for Oncologic Questions?</strong></td>
<td>Irene Burger (Baden, Switzerland): 33</td>
</tr>
<tr>
<td><strong>Beyond Oncological Applications</strong></td>
<td>Alexander Hammers (London, United Kingdom) 34</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CME 7 - Physics + Dosimetry Committee: <strong>Developments and Challenges in Theranostics</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Where Are We with Theranostic Imaging Today?</strong></td>
<td>Lioe-Fee de Geus-Oei (Leiden, Netherlands) 36</td>
</tr>
<tr>
<td><strong>Terbium Radioisotopes for Theranostics, What to Expect?</strong></td>
<td>Cristina Müller (Villingen, Switzerland) 37</td>
</tr>
<tr>
<td><strong>Quantitative Theranostic Imaging - Challenges and Opportunities</strong></td>
<td>Mark Konijnenberg (Rotterdam, Netherlands) 38</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CME 8 - Radiation Protection + Dosimetry Committee: <strong>Pregnancy and Breastfeeding in the Context of Nuclear Medicine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status of Guidelines on Breastfeeding</strong></td>
<td>Sigrid Leide-Svegborn (Malmo, Sweden) 40</td>
</tr>
<tr>
<td><strong>The Pregnant Patient - Risks for the Foetus</strong></td>
<td>François Jamar (Brussels, Belgium) 41</td>
</tr>
<tr>
<td><strong>How to Estimate the Radiation Doses?</strong></td>
<td>Marta Cremonesi (Milan, Italy) 42</td>
</tr>
</tbody>
</table>
### FRIDAY, OCTOBER 22, 2021

**CME 9 - Radiopharmacy + Drug Development Committee:**

*Back to the Future - New Kit-Based Approaches for Labelling Radiopharmaceuticals (⁶⁸Ga, Al[¹⁸F]F,...)*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labelling Cold Kit With ⁶⁸Ga - The Future is Bright</td>
<td>Clément Morgat (Bordeaux, France)</td>
<td>44</td>
</tr>
<tr>
<td>Al[¹⁸F]F: From Modules Toward a Kit-Based Radiofluorination?</td>
<td>Chiara Da Pieve (London, UK)</td>
<td>45</td>
</tr>
<tr>
<td>Regulatory Aspects of Cold Kit - Based Radiopharmaceuticals in the EU</td>
<td>Oliver Neels (Dresden, Germany)</td>
<td>46</td>
</tr>
</tbody>
</table>

**CME 10 - Thyroid + Oncology & Theranostics Committee:**

*Radiouclide Therapies - Management of Side Effects and Complications*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radioiodine Therapy in Thyroid Cancer</td>
<td>Markus Luster (Marburg, Germany)</td>
<td>48</td>
</tr>
<tr>
<td>Peptide Receptor Radiouclide Therapy - Management Of Side Effects And Complications</td>
<td>Gopinath Gnanasegaran (London, UK)</td>
<td>49</td>
</tr>
<tr>
<td>¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer - A Game Changer?</td>
<td>Sarah M. Schwarzenböck (Rostock, Germany)</td>
<td>50</td>
</tr>
</tbody>
</table>

**CME 11 - Bone & Joint Committee:**

*New Concepts for Imaging and Therapy of Bone Metastases*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclear Imaging of Bone Metastases</td>
<td>Helle D. Zacho (Aalborg, Denmark)</td>
<td>52</td>
</tr>
<tr>
<td>Radionuclide Therapy of Bone Metastases</td>
<td>Ali Afshar-Oromieh (Bern, Switzerland)</td>
<td>53</td>
</tr>
<tr>
<td>Ablative Irradiation Of Bone Metastases</td>
<td>Piet Dirix (Antwerp, Belgium)</td>
<td>54</td>
</tr>
</tbody>
</table>

**CME 12 - Paediatric Committee:**

*Nuclear Medicine in the Evaluation of Child Abuse*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Aspects Of Child Abuse</td>
<td>Hadas Yechiam (Kfar Saba, Israel)</td>
<td>56</td>
</tr>
<tr>
<td>Nuclear Medicine in the Evaluation of Child Abuse</td>
<td>Laura Drubach (Boston, USA)</td>
<td>57</td>
</tr>
<tr>
<td>Radiological Aspects of Child Abuse</td>
<td>Chiara Giraudo (Padua, Italy)</td>
<td>58</td>
</tr>
</tbody>
</table>

### SATURDAY, OCTOBER 23, 2021

**CME 13 - Translational Molecular Imaging & Therapy + Oncology & Theranostics Committee:**

*Immunotheranostics*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunotherapy and Nuclear Medicine diagnostics - Where do we Stand?</td>
<td>Elisabeth G. E. de Vries (Groningen, Netherlands)</td>
<td>60</td>
</tr>
<tr>
<td>Combining Immunotherapy and Radiation - Is the Whole More than the Sum of its Parts?</td>
<td>Fernanda Herrera (Lausanne, Switzerland)</td>
<td>61</td>
</tr>
<tr>
<td>Nuclear Medicine Immunotheranostics - Synergisms and Antagonisms</td>
<td>Niklaus Schaefer (Lausanne, Switzerland)</td>
<td>62</td>
</tr>
</tbody>
</table>

**CME 14 - Drug Development + Translational Molecular Imaging & Therapy Committee:**

*Probing Tumour Metabolism - An Update*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging Nucleoside Transport for Monitoring Targeted Therapy in Cancer</td>
<td>Francesca Iomelli (Naples, Italy)</td>
<td>64</td>
</tr>
<tr>
<td>Illuminating Metabolic Heterogeneity and Vulnerabilities in Lung Cancer</td>
<td>David Lewis (Glasgow, UK)</td>
<td>65</td>
</tr>
<tr>
<td>Imaging Tumour Metabolism and its Heterogeneity with MRI</td>
<td>Ferdia Gallagher (Cambridge, UK)</td>
<td>66</td>
</tr>
</tbody>
</table>
Dear Colleagues, dear Friends,

On behalf of the European Association of Nuclear Medicine, it is my honour to invite you to the 34th Annual EANM Congress. The event will run virtually from 20 to 23 October 2021.

Despite the difficult time we are experiencing due to the pandemic, nuclear medicine continues to grow both in diagnostic imaging and therapy. New radiopharmaceuticals which facilitate the study and treatment of new targets are being introduced, more and more protocols which cover unmet clinical needs and new applications are running, and the use of nuclear medicine procedures is increasingly being incorporated into clinical practice and guidelines. This success remains related to that very peculiar characteristic of our specialty, namely, its functional approach to medicine. This is mainly true with respect to imaging, but also for therapy.

In recent years we have proudly celebrated the status of the EANM Congress as the world’s leading meeting for nuclear medicine. In 2019, for example, we reached almost 7000 participants, a truly memorable record. As we all know, the pandemic of 2020 forced all events to move to a virtual format and we did our best to prepare a great event. We succeeded in keeping all of our scientific programmes running with 11 parallel channels and received excellent feedback from participants. As mentioned, we are unable to return to the complete live format we are used to and would have all hoped for in 2021. Therefore, we have planned a great event with a full scientific programme once more, but have arranged some significant improvements after the lessons learnt last year. In 2021, the pre-congress symposia will run a couple of weeks before the congress, which, as a result, has been shortened by one day. Furthermore, most of the several parallel tracks will not run according to the traditional time sequence but will always be available on demand to facilitate access and productivity for attendees.

In summary, we are working on providing you a congress with superb and comprehensive scientific content as well as a lot of other features to make your participation enjoyable whatever you are looking to achieve:

Stefano Fanti
EANM Congress Chair 2020-2022
# CME Programme at a Glance

<table>
<thead>
<tr>
<th>Day</th>
<th>Session</th>
<th>Time</th>
<th>Committee</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday, October 20</strong></td>
<td>CME 1</td>
<td>10:15-11:45</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Prostate Cancer - Greatest Hits</td>
</tr>
<tr>
<td></td>
<td>CME 2</td>
<td>12:00-13:30</td>
<td>Physics Committee</td>
<td>AI in Radiomics</td>
</tr>
<tr>
<td></td>
<td>CME 3</td>
<td>16:15-17:45</td>
<td>Inflammation &amp; Infection Committee</td>
<td>The Battle Continues - WBC Scan vs FDG PET/CT</td>
</tr>
<tr>
<td></td>
<td>CME 4</td>
<td>18:00-19:30</td>
<td>Neuroimaging Committee</td>
<td>Imaging Neuroinflammation - Everything You Always Wanted to Know But Were Afraid to Ask</td>
</tr>
<tr>
<td><strong>Thursday, October 21</strong></td>
<td>CME 5</td>
<td>09:00-10:30</td>
<td>Cardiovascular + Inflammation &amp; Infection Committee</td>
<td>Infiltration, Infection and Infiltrative Nuclear Cardiovascular Diseases - Think Nuclear!</td>
</tr>
<tr>
<td></td>
<td>CME 6</td>
<td>10:45-12:15</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Quo vadis PET/MRI?</td>
</tr>
<tr>
<td></td>
<td>CME 7</td>
<td>15:05-16:35</td>
<td>Physics + Dosimetry Committee</td>
<td>Developments and Challenges in Theranostics</td>
</tr>
<tr>
<td></td>
<td>CME 8</td>
<td>16:50-18:20</td>
<td>Radiation Protection + Dosimetry Committee</td>
<td>Pregnancy and Breastfeeding in the Context of Nuclear Medicine</td>
</tr>
<tr>
<td><strong>Friday, October 22</strong></td>
<td>CME 9</td>
<td>09:00-10:30</td>
<td>Radiopharmacy + Drug Development Committee</td>
<td>Back to the Future - New Kit-Based Approaches for Labelling Radiopharmaceuticals ((^{68})Ga, (^{18})F,...)</td>
</tr>
<tr>
<td></td>
<td>CME 10</td>
<td>10:45-12:15</td>
<td>Thyroid + Oncology &amp; Theranostics Committee</td>
<td>Radionuclide Therapies - Management of Side Effects and Complications</td>
</tr>
<tr>
<td></td>
<td>CME 11</td>
<td>15:05-16:35</td>
<td>Bone &amp; Joint Committee</td>
<td>New Concepts for Imaging and Therapy of Bone Metastases</td>
</tr>
<tr>
<td></td>
<td>CME 12</td>
<td>16:50-18:20</td>
<td>Paediatrics Committee</td>
<td>Nuclear Medicine in the Evaluation of Child Abuse</td>
</tr>
<tr>
<td><strong>Saturday, October 23</strong></td>
<td>CME 13</td>
<td>09:00-10:30</td>
<td>Translational Molecular Imaging &amp; Therapy + Oncology &amp; Theranostics Committee</td>
<td>Immunotheranostics</td>
</tr>
<tr>
<td></td>
<td>CME 14</td>
<td>10:45-12:15</td>
<td>Drug Development + Translational Molecular Imaging &amp; Therapy Committee</td>
<td>Probing Tumour Metabolism - An Update</td>
</tr>
</tbody>
</table>

---

**All Session Times Refer to Central European Summer Time (CEST)**
Prostate Cancer - Greatest Hits
Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein expressed in normal prostatic tissue and particularly overexpressed in the adenocarcinoma of the prostate. In the last decade, it has been in the spotlight with the development of PSMA ligands for positron emission tomography (PET) imaging and PSMA-targeted therapies for prostate cancer. PSMA-PET has a high detection rate for prostate cancer lesions both in the setting of initial staging and of biochemical recurrence. However, detectability of lesions depends on PSMA expression of the tumor tissue, which is markedly heterogeneous. It can be expressed in the cytoplasm and in the membrane of cells in higher or lower intensity, and the percentage of cells with significant PSMA expression seems to be determinant for PET imaging. Around 6-10% of primary prostate adenocarcinoma are PSMA-negative on immunohistochemistry and around 10% of them are negative on PSMA-PET. In patients with metastatic lesions, PSMA-expression can vary between lesions and metastasis sites as well as throughout the course of the disease with the development of castration-resistant prostate cancer and with the use of androgen-deprivation therapy. It has also been shown to correlate with parameters such as tumour grade and patient’s serum PSA level. In this presentation it will be discussed what is known about PSMA expression of prostate cancer that can have an effect on PSMA-PET imaging.

References:

PSMA PET IN PRIMARY STAGING - READY FOR PRIME TIME?
THE UROLOGIST’S PERSPECTIVE

OTTO ETTALA (TURKU, FINLAND)

PSMA-targeted PET imaging and radionuclide therapies have rapidly gained popularity in staging, restaging and treatment of men with prostate cancer. Currently the main indication of PSMA PET is restaging after biochemical recurrence (1). With the increasing scientific knowledge on the pearls and pitfalls of PSMA PET imaging, are we now ready to override whole body contrast enhance computed tomography (CT) and bone scintigraphy (BS) with PSMA PET in primary staging setting?

So far, there are only few trials demonstrating the superiority of PSMA PET compared to CT and BS in primary staging of prostate cancer, in terms of sensitivity, diagnostic accuracy and changes in treatment decision (2,3). However, whether patients truly benefit from this increased sensitivity and earlier detection of metastases is of question. Due to lack of randomized trials showing the benefit of PSMA PET on improved patient outcomes i.e. development of metastatic disease, castration resistance or death, PSMA PET is still considered as experimental both in European and American urology guidelines (1,4).

Due to its superiority in prostate cancer detection PSMA PET is a very promising technique ready for prime time. However, as a standard in clinical practice, CT and BS still stand their ground in primary staging, until more evidence on the effect of PSMA PET on patient outcomes is available.

References:

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has been successfully implemented for the restaging of patients with prostate cancer after primary treatment. Several international guidelines recognize the indication for using PSMA PET/CT in biochemical relapse setting, based on the high accuracy of this technique to detect local recurrence and/or metastatic lesions, even at very low prostate-specific antigen (PSA) values.

Nevertheless, the clinical questions ‘We see more, but do we treat better?’ and ‘Do our patients have survival benefit using PSMA PET?’ are more actual than ever. Therefore, this presentation will focus on the new insights regarding the PSMA PET, in an attempt to find the scientifically-proven answers. Aspects related to the accurate criteria for PSMA PET interpretation, the newly PSMA oligometastatic concept, the PSMA-induced shift in clinical management and the role of PSMA to guide metastasis-directed therapy will be discussed. Finally, new research ideas will be proposed to facilitate the interaction between the nuclear medicine community and our clinical partners, PSMA believers or not.

References:

PSMA PET FOR CASTRATION-RESISTANT PROSTATE CANCER - HOW FAR HAVE WE COME?

**WOLFGANG PETER FENDLER (ESSEN, GERMANY)**

The addition of PSMA PET to conventional imaging of castration-resistant prostate cancer (CRPC) leads to the PCWG3 subgroup upstaging in 30% of patients [1]. PSMA PET detects more lesions and regions of disease in all subgroups, especially in patients with non-metastatic CRPC (nmCRPC) by conventional imaging [2]. Detection of metastases by PSMA PET was associated with short progression-free survival in patients with biochemically recurrent disease [3]. PSMA PET-guided oligometastases-directed therapy resulted in prolonged progression-free survival when compared with observation only [4]. Gafita et al. assessed the prognostic value of PSMA PET for outcome following 177Lu-PSMA RLT in 270 patients from multi-center prospective and retrospective patient cohorts [5]. PSMA expression and disease stage by PET were associated with biochemical progression-free survival and overall survival following 177Lu-PSMA. PSMA PET findings and clinicopathologic parameters were combined in a nomogram for baseline prognostic assessment [5]. In summary, PSMA PET leads to considerable upstaging with higher accuracy for the detection of metastases in patients with oligometastatic, nmCRPC, or mCRPC by conventional imaging. Disease extent by PSMA PET is associated with short survival in patients with recurrent or advanced metastatic disease.

**References:**

AI in Radiomics
Deep learning is now ubiquitous in medical image analysis. Its success is due to unprecedented generalization ability, i.e., its capacity to make accurate predictions from samples not seen during model training. Two necessary conditions for generalization are: 1 - sufficient training samples to accurately capture the underlying true data distribution and 2 - deployment (testing) conditions sufficiently close to training conditions. These two requirements are generally not optimally met in medical imaging due to the relative scarcity of data and to multiple sources of heterogeneity regrouped under the term domain shift. In particular, multi-center studies, a typical way to address data scarcity, generally aggravate the domain shift compared to single-center studies.

Driven by the popularity of deep learning in medical imaging, a growing number of works are recently being devoted to mitigating these issues through advanced domain adaptation techniques. This talk will provide a systematic overview of these methods and their associated challenges for various downstream applications including but not limited to image segmentation and radiomics analyses. Both conventional mitigation and advanced deep strategies at the image and the feature level will be discussed. Examples in quantitative molecular imaging will be given.

References:

POTENTIAL ROLE OF AI AND RADIOMICS IN ONCOLOGY

REFERS TO CME TALK: AI AND RADIOMICS FOR ONCOLOGY APPLICATIONS

MARTINA SOLLINI (MILAN, ITALY)

In the era of precision medicine, there is the need of noninvasively predict patients’ outcome informing clinicians about the risks of recurrence, treatment effectiveness, and toxicity development. AI and radiomics, offering the advantage to explore and to non-invasively assess tumor biology through conventional medical imaging, can be extremely valuable in this regard [1]. Moreover, AI has been demonstrated to be a reliable strategy for model development, it is technically unbiased (it learns from experience, i.e. data), it may constantly improve working through automated and reproducible processes, ultimately requiring less human resources, and it constitutes a promising solution for AI-based research [2-4]. Therefore, it is not wonder that the clinical and scientific interest in AI and radiomics has significantly increased in the recent years [2]. Nonetheless, we are far from the scenario projected by the experts in the field according to which AI and radiomics would have replaced doctors including imagers. Indeed, although AI and radiomics studies resulted promising, they are still not mature enough to be implemented in the clinical setting and be widely used [5,6]. To successfully implement AI and radiomics in the real-clinical world sustainable, rigorous, and multidisciplinary research plan are needed for study design, model development (image preprocessing), training (labeling and/or features extraction) and testing (reproducibility) [2,4-7]. In this CME session we will describe the potential role of AI and radiomics in oncology.

References:

POTENTIAL ROLE OF AI AND RADIOMICS IN CARDIAC IMAGING

CHRISTOPH RISCHPLER (ESSEN, GERMANY)

Myocardial perfusion imaging using SPECT remains one of the most frequently performed examinations in nuclear medicine. This fact and the fact that the examination protocols are often standardised make this application and nuclear cardiology in general particularly interesting for AI and radiomics (1).

One of the first applications of AI is likely to be to facilitate the work of doctors by relieving them of tedious and time-consuming steps. Possible promising applications in this field are the automatic determination of the valve plane during the reangulation of reconstructed image data (2). Even a fully automated evaluation of image data has already been described, which provides similarly good results compared to an assessment by experts (3). Furthermore, there are approaches to evaluate the image data together with other parameters that arise in the clinic or during the examination (such as symptoms, ECG abnormalities or pump function in SPECT) in order to improve the diagnosis of obstructive coronary artery disease (4). Last but not least, there are first studies that evaluated the possibility of a prognostic prediction by means of AI with regard to the occurrence of e.g., major adverse cardiac events (MACE) with the aid of image data and other clinical parameters. In contrast to humans, who mainly evaluate the acquired imaging data, AI allows for the integration of a large number of different parameters. Initial studies show that the AI approach may thus be superior to humans in terms of predicting MACE (5).

This lecture will discuss these and other promising fields of application in nuclear cardiology and thus possibly provide a glimpse into the future.

References:

WHAT MAY THE COMBINATION OF RADIOMICS AND DEEP LEARNING BRING TO SPECT AND PET OF THE BRAIN?

REFERS TO CME TALK: WHAT MAY AI AND RADIOMICS BRING IN NEUROIMAGING?

RALPH BUCHERT (HAMBURG, GERMANY)

Radiomics is based on the extraction of quantitative features from medical images and the subsequent mathematical analysis of these features to support the interpretation of the images [1]. The quantitative features used in radiomics often have a clear interpretation such as size, shape and textural features of structures in the image. The mathematical analysis of the extracted features often is based on statistical models derived by machine learning methods such as support vector machines.

Deep learning is an umbrella term for machine learning methods based on deep artificial neural networks with multiple layers resulting in a very large number of trainable parameters [2]. Fully data-driven approaches with deep convolutional neural networks (CNN) work end-to-end with no human knowledge built in, that is, without prior feature extraction ("image in, result out"). The CNN itself learns the relevant features from a sufficiently large number of training cases. Fully data-driven deep CNN have outperformed conventional machine learning methods with engineered features in many medical imaging tasks [3]. However, deep CNN are often considered black-box models so that improved performance comes at the price of reduced transparency. Deep CNN can also be used for the mathematical analysis of radiomics features extracted from the medical images in a pre-processing step.

This talk will discuss strengths and limitations of radiomics and deep CNN in radionuclide brain imaging using the example of dopamine transporter SPECT in the diagnosis of clinically uncertain parkinsonian syndromes [4]. Particular emphasis will be placed on stability of the models with respect to variable site-, camera- or scan-specific image characteristics ("domain adaption") [5] and on model transparency ("explainable AI"). Finally, the utility of using deep CNN for the analysis of predefined radiomic features will be discussed.

References:

The Battle Continues - WBC Scan vs FDG PET/CT
Musculoskeletal infections represent a serious medical challenge in healthcare, as establishing a correct diagnosis can be very complicated, and the spread of infection or sepsis can be life-threatening. In addition, these pathologies have a high morbidity and treatment can have a major impact on daily life, sometimes requiring prolonged surgeries that can lead to amputation in some cases\(^1,2\). Since laboratory tests are relatively non-specific, imaging explorations are necessary to obtain the correct diagnosis, although morphological alterations take time to appear on radiological studies. For this reason, the different modalities of nuclear medicine are important as they provide functional/metabolic information in early stages of the disease, often before morphological changes appear\(^3\). They allow to study the pathophysiology of these processes and play an important role in the diagnosis, characterisation, and monitoring of musculoskeletal infectious diseases. Although PET/CT is emerging as a diagnostic tool in musculoskeletal infection/inflammation, white blood cell scintigraphy (WBC) currently remains as the gold standard in nuclear medicine when infection is suspected, which is decisive for the differential diagnosis of infection/inflammation in peripheral osteomyelitis, diabetic foot, periprosthetic infection, etc\(^4\). In addition, the use of SPECT/CT provides the possibility to acquire anatomical and functional images in the same study improving the sensitivity and specificity of planar images, with better localization and relevant anatomical data for surgical treatment planning, obtaining detailed knowledge of bone status, implant integrity, as well as distribution/extension of infection with a sensitivity of 100% and a specificity of 89-97\(^6\)\(^7\).

This presentation reveals the role of the WBC with its advantages/disadvantages and clinical indications, to achieve an adequate diagnosis of infection and inflammation.

References:

FDG-PET FOR MUSCULOSKELETAL INFECTIONS - PROS AND CONS

ZOHAR KEIDAR (HAIFA, ISRAEL)

Musculoskeletal infections are a serious health condition which is difficult to diagnose. Treatment of a musculoskeletal infection often requires a long time and/or costly procedures which can be avoided if musculoskeletal infection is excluded. Timely identification and precise localization of musculoskeletal infections by imaging techniques are critical for early initiation of treatment and can have a significant impact on patient outcome. Nuclear medicine plays a significant role in the evaluation of infection. While bone and labeled WBC scans are used traditionally for the investigation of bone infection, the contribution of FDG PET/CT in patients with suspicious musculoskeletal infections was also established. 18F-FDG is transported into cells via glucose transporters and is phosphorylated by hexokinase but not metabolized further. In infection and inflammation processes, there is an increased number and expression of glucose transporters by activated inflammatory cells and an increased affinity of these transporters for 18F-FDG. PET/CT is a relatively high-resolution imaging test that provides precise radiopharmaceutical localization. The diagnostic performance of FDG PET or PET/CT was shown to be excellent in different groups of patients with suspicious osteomyelitis including patients with diabetic foot complications, hip and knee prosthetic infections and infectious spondylodiscitis. Overall, based on the available evidence, FDG PET/CT is considered as a good diagnostic tool for the detection of musculoskeletal infections. This CME presentation will provide a review of the current role of FDG PET/CT in the investigation of musculoskeletal infections, strengths, weaknesses, pitfalls and advantages over other imaging modalities.

References:

4. Treglia G. Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses. Contrast Media Mol Imaging. 2019; 2019: 3018349.
For a long time, radiolabelled white blood cells (WBC) SPECT/CT has been regarded as the mainstay of imaging in chronic infection of bones and joints. Thereafter, the technique has been applied to cardiovascular infections with consistently high specificity in the following settings:

1. Prosthetic vascular graft infections: many studies support the excellent diagnostic value of WBC scintigraphy in this indication, with both excellent sensitivity and specificity.

2. Infective endocarditis: studies that enrolled patients suspected of endocarditis on either native or prosthetic valves showed very good performances 1, 2, 3.

3. Cardiac Implantable Electronic Devices (CIED) and Left Ventricular Assist Device (LVAD) infections: A large body of literature supports the use of WBC SPECT/CT to improve the diagnostic performances of the Duke-Li score, particularly when CIED infection was initially graded as possible 4.

Consequently, WBC SPECT/CT is now part of the diagnostic flowchart in European guidelines for infective endocarditis and CIEDs infections 5, 6. In some clinical situations such as short delay after cardiac surgery, presence of surgical adhesives, intense host reaction against prosthetic material, the excellent specificity of WBC SPECT/CT allows to overcome the risk of false-positives that may occur with FDG PET.

However, the scan suffers some limitations. First of all the labelling procedure is long, cumbersome and requires a specific lab approved by health authorities due to the handling of blood products. In addition, the long acquisition procedure can be uncomfortable for patients in poor general condition. Third, the diagnostic sensitivity is somewhat lower compared to FDG PET/CT. Taken together, these limitations mean that WBC SPECT/CT should be considered a second line test after inconclusive FDG PET/CT most commonly. Finally, careful interpretation as well as early imaging in the course of the disease are critical to avoid false negative results and to achieve maximal impact on patients’ management.

References:

5. Habib G et al, European Heart Journal 36, 3075-3128
FDG-PET FOR CARDIOVASCULAR INFECTIONS - PROS AND CONS

LUCIA LECCISOTTI (ROME, ITALY)

Cardiovascular infections include a group of conditions associated with significant morbidity and mortality and involve a relevant burden of diagnostic workup. Early and accurate diagnosis is crucial for adequate patient management. FDG-PET is a well-established imaging modality in cardiovascular infection diagnosis. It is included in the investigation algorithms of different cardiovascular infections and is often performed in complex cases. In addition to defining the presence and extent of cardiovascular infection, whole body FDG-PET can demonstrate extra-cardiac embolic foci of infection or a primary source of infection. The use of FDG-PET for the assessment of response to treatment in cardiovascular infections is also increasing over the years. However, interpretation of these studies can be challenging in light of possible false positive or negative cases and, occasionally, due to reader’s unfamiliarity with typical cardiovascular findings.

The objective of this presentation is to review the current role, diagnostic criteria, optimal protocol and pitfalls of FDG-PET imaging in several clinical scenarios related to cardiovascular infections such as prosthetic and native valve, cardiac implantable electronic device, left ventricular assist device and vascular graft.

References:

Imaging Neuroinflammation - Everything You Always Wanted to Know, But Were Afraid to Ask
BACKGROUND OF TSPO AND NON-TSPO TARGETS AND THEIR RADIOTRACERS

MATTHIAS BRENDEL (MUNICH, GERMANY)

This CME talk provides the molecular background of neuroinflammation radiotracer targets. A focus will be placed on the translocator protein (TSPO) and its known roles in cell biology and pathophysiology of neuroinflammatory diseases. Advantages and disadvantages of TSPO as a tracer target in neuroinflammatory conditions will be outlined according to the biological background. Moreover, the talk will provide an overview on existing TSPO PET tracers and their sensitivity to the rs6971 polymorphism. Established and recently explored non-TSPO targets of neuroinflammation such as monoaminoxidases, cyclooxygenases and triggering receptor expressed on myeloid cells 2 (TREM2) will be outlined. Here, details of the talk will highlight gene expression and neuropathological findings related to non-TSPO targets in neurodegenerative diseases and other neuroinflammatory conditions. Novel opportunities to uncover the specificity of neuroinflammation tracers will be highlighted.

References:

CME Session
October 20
18:00 - 19:30

EANM’21 WORLD LEADING MEETING
OCTOBER 20 – 23, 2021 | VIRTUAL

IMAGING NEUROINFLAMMATION WITH TSPO LIGANDS - A CRITICAL REAPPRAISAL

BART VAN BERCKEL (AMSTERDAM, NETHERLANDS)

In vivo imaging of neuroinflammation with TSPO receptors (previously called PBR receptors) has been an active research topic in nuclear medicine for almost 50 years. Although substantial progress has been made, the field is still struggling with the question which tracer and quantitative method to use and for which clinical indications. In this CME talk, we would like to go back to basics and review the steps that have to be taken to validate new PET tracers “from benchtop to bedside”. We will apply this pathway to the development of TSPO tracers and provide a review of the level of validation of current TSPO tracers. Specific TSPO imaging related caveats will be discussed.

References:
Neuroinflammation involves glial activation (astrocytes, oligodendrocytes and microglia) and infiltration of peripheral immune cells such as macrophages, monocytes and neutrophils. TSPO radioligands are currently the most widely used radioligands to visualize neuroinflammation, however they have some drawbacks. Also, the cellular source of neuroinflammation may differ across different diseases and in the different stages of the disease. For example, in amyotrophic lateral sclerosis a temporal pattern of glial type TSPO expression exists: in early phase most TSPOs are expressed on microglia, whereas this may shift to astrocytes in later phases of the disease [1]. So non-TSPO neuroinflammation-related radioligands targeting the entire range of immune cells are needed.

We will discuss the following neuroinflammation-related targets [2, 3]
- monoamine oxidase-B, mainly located in astrocytes
- cyclooxygenase, the rate limiting enzyme in the formation of prostaglandins from arachidonic acid
- the cannabinoid-2 receptor and colony-stimulating factor 1 receptor colocalized mainly with microglia
- the chemokine receptor CX3CR1 expressed in lymphocytes and microglia
- the purinergic receptors: P2X7 expressed on pro-inflammatory microglia and P2Y12 expressed on anti-inflammatory
- adaptive immune-cell imaging biomarkers as central nervous system-infiltrating B cells are key drivers of maladaptive immune responses in for instance multiple sclerosis

In this session we will focus on different non-TSPO radioligands with their respective cellular targets and the relevance in different diseases.

References:
Inflammation, Infection and Infiltrative Cardiovascular Diseases - Think Nuclear!
Sarcoidosis is a systemic granulomatous disorder of unknown etiology characterized by significant clinical heterogeneity. Symptomatic cardiac involvement occurs in 2-5% of patients with systemic sarcoidosis and the clinical presentation (conduction abnormalities, tachy-bradyarrhythmia and heart failure) is dependent on the disease location, extent and activity. However, autopsy and imaging studies report a substantially higher prevalence of cardiac involvement ranging from 25% in North America to more than 50% in Japan. In addition, isolated cardiac sarcoidosis may be more prevalent than reported with estimates of 20%. Importantly, patients with cardiac involvement have a poorer prognosis and cardiac sarcoidosis (CS) account for up to 25% of disease-related deaths.

The diagnosis of CS remains very challenging due to the non-specific clinical presentation and the focal infiltration of the heart hereby limiting the diagnostic utility of endomyocardial biopsies. Several diagnostic criteria have been proposed with the most recent being the 2016 guidelines of the Japanese Circulation Society and the 2014 Heart Rhythm Society (HRS) criteria. Based on the available data \([^{18}\text{F}]\text{FDG-PET/CT imaging is now included in both criteria as a useful technique to investigate suspected cardiac sarcoidosis.}[^{18}F]\text{FDG-PET/CT combined with perfusion imaging to detect both inflammation and fibrous replacement of the myocardium provides important diagnostic and prognostic information and serves as a valuable tool to monitor treatment response.}\]

This CME presentation will provide an overview of the current role of nuclear imaging in the diagnosis and management of patients with cardiac sarcoidosis.

References:

**THE ROLE OF NUCLEAR MEDICINE IN CARDIAC AMYLOIDOSIS**

**REFERS TO CME TALK: CARDIAC AMYLOIDOSIS**

Tanja Kero (Uppsala, Sweden)

Amyloidosis is a systemic disease in which different types of misfolded proteins, amyloid fibrils, are deposited extracellularly in various tissues, leading to progressive organ dysfunction (1). Radionuclide imaging plays a unique role in the non-invasive diagnosis of cardiac amyloidosis. 99mTc-labeled bone-seeking tracers (99mTc-PYP, -DPD and -HMDP) have been used for decades and have an established role in the diagnosis of ATTR cardiac amyloidosis (2). However, the uptake of the bone-seeking tracers is related to the patients' transthyretin amyloid fibril composition and can be negative in certain types of hereditary ATTR (3), they cannot be used in imaging of cardiac AL and they have not proven useful for assessment of disease progression (4). Amyloid-binding PET tracers (11C-PIB, 18F-florbetapir and 18F-florbetaben) can reliably image both AL and ATTR cardiac amyloidosis (5), including ATTRv where bone-seeking SPECT tracers have been negative (6) and the PET tracers can more readily be used in quantification of the amyloid deposits. Radionuclide imaging has also been used in assessment of pathophysiology in cardiac amyloidosis: 123I-mIBG has shown sympathetic cardiac denervation in patients with ATTR (7), PET myocardial perfusion imaging have shown reduced stress myocardial blood flow (8) and 11C-acetate PET has shown impaired myocardial oxidative metabolism and external efficiency (9).

References:

Endocarditis is an infection of the inner lining of the heart. Its initial presentation is diverse with non-specific symptoms such as fever and malaise, and diagnosis can be challenging. The presence of prosthetic materials (e.g. valve replacements, grafts and implantable devices and associated leads) is a predisposing factor.

In the past years a growing body of evidence has cemented the role of $^{18}$F-FDG PET/CT for the diagnosis of endocarditis, especially in challenging cases and when prosthetic material is present.

In native valve endocarditis, $^{18}$F-FDG PET/CT has a relatively poor sensitivity for valve infection in the order of 30%\(^2\), but is of value in diagnosing metastatic infectious foci and portes d’entrée.

In prosthetic valve endocarditis, $^{18}$F-FDG PET/CT is more accurate in diagnosing valve infection with a pooled sensitivity of 86% in a recent meta-analysis\(^3\). For correct interpretation of findings it is important to be aware of a number of known confounders\(^4,5\), and in cases where $^{18}$F-FDG PET/CT is equivocal radiolabeled leukocyte scintigraphy can be of additional value\(^6\).

Multimodality imaging including echocardiography and CT angiography is almost always involved in endocarditis, and an “endocarditis team” consisting of cardiologists, cardiac surgeons, microbiologists and imaging specialists working together is recommended to ensure swift diagnosis and treatment\(^7\).

References:

Large vessel vasculitis (LVV) is increasingly recognized as a common systemic inflammatory disease with considerable morbidity and mortality. The most prevalent forms of LVV are Giant Cell Arteritis (GCA), and Takayasu’s Arteritis (TA), both of which cause progressive luminal narrowing of large arteries with subsequent tissue ischemia and constitutional and/or localized symptoms. In LVV and TA, the vessel walls are infiltrated by glucose consuming macrophages and can therefore be readily visualized by 18F-Fluorodeoxyglucose (FDG) PET/CT (1). However, the disease burden, severity and extent at presentation vary greatly, and timely treatment by immunosuppressive therapy is necessary to mitigate the complications associated with the disease. These issues pose particular problems for the imaging physician. First, LVV in smaller cranial arteries (c-GCA) surrounded by tissues with at least some FDG uptake may be hard to detect due to poor signal-to-noise ratios (2). Second, the pattern of disease varies greatly from affecting the entire aortic vasculature to limited segments of the cranial vasculature rendering pattern recognition difficult. Third, large vessel low grade inflammation is frequently encountered in older patients with cardiovascular disease making it harder to discriminate between LVV and more benign variants of vascular disease (3). Fourth, newer PET/CT reconstruction algorithms tend to overestimate FDG uptake in smaller structures such as vessel walls (4). Fifth, patients have often been treated with corticosteroids prior to their FDG PET/CT resulting in acutely inhibited macrophage FDG uptake and reduced sensitivity to diagnose LVV (5).

This presentation will therefore focus on the initial diagnosis of LVV including the most frequent patterns of disease, pathology thresholds of vessel wall-background ratios, and the effects of corticosteroid treatment on FDG PET/CT diagnostic accuracy. Finally, some potential image interpretation pitfalls will be highlighted.

References:


Whole-body hybrid PET/MR imaging has been used since its introduction in 2010 in clinical and research settings for diagnosis, staging and restaging, assessment of response to treatment, and radiation therapy planning [1]. While clinical application today is at full swing, on the methodological side, PET/MR demanded for new techniques and innovative solutions [2]. Particularly attenuation correction (AC) and scatter correction (SC) have been hot topics of debate and they continue to be [1,2].

Latest methodological developments in PET/MR attenuation and truncation correction help to further improve the robustness of PET/MR examinations and, furthermore, improve quantification of PET data [3-5]. The application of PET/MR in prostate cancer diagnostics has profited from improved scatter correction methods [6,7]. Recently, deep-learning methods have successfully been used to generate pseudo-CT AC maps from MR data for accurate AC in pelvic imaging applications [8].

The integration of radiofrequency coils with appropriate hardware attenuation correction methods broadens the spectrum of oncologic PET/MR applications further [9]. Recent technical developments aim towards the integration of PET/MR into the concept of radiation therapy treatment planning [10]. This presentation will provide an overview and outlook of the aforementioned current methodological developments.

References:

PET/MR has the potential to introduce new applications for PET imaging. With the increasing number of studies looking into the added value of MRI information for PET examinations molecular imaging with PET/MR can improve not only the local staging but also the assessment of tumor heterogeneity in one exam, examples are:

Primary tumor detection: Initial data showed that PSMA-PET/MR can successfully be used to guide biopsies, with a significantly higher specificity compared to mpMRI [1]. Others also confirmed the improved accuracy of PSMA PET/MR over mpMRI for tumor detection [2]. More resent work with direct combination of PSMA PET and mpMRI in correlation with histopathology and immunohistochemistry now allows us to go a step further and increase our understanding of tumor heterogeneity and behavior, this could be the base for further improvement of our diagnostic tools in the detection of prostate cancer.

Improved staging: The superior soft tissue contrast of PET/MR over PET/CT enables an improved T-staging in a variety of tumor entities. Prostate cancer is an example where the added information of PSMA-PET did even further improve the sensitivity for extracapsular extension or seminal vesicle involvement compared to mpMRI in intermediate to high risk prostate cancer patients [3]. Improved local staging with PET/MR over was also suggested for cervical cancer e.g. with the combination of Radiomics analysis to accurately predict nodal stage [4]. Also in head and neck cancer the improved local assessment of a directly combined PET/MR over PET/CT has been shown in the past. Now new tracers, such as the FAPI ligand have been investigated in this setting as well, showing that FAPI PET/MR might even outperform FDG PET/MR [5].

Improved tumor assessment: Patient selection for therapy is becoming more and more important with the success of internal radiotherapy. An early study combining hepatobiliary MRI contrast with 68Ga-DOTATOC showed an improved lesion detection over PET alone, and might in the future be instrumental for the detection of SSTR-2 negative disease that will not respond well to therapy. PET/MR has the potential to become a one-stop shop modality for patient selection for internal radiotherapy.

References:

PET-MR was developed with the success of PET-CT in mind, a dual (albeit not simultaneous) modality which had revolutionised oncological imaging from 2000 onwards: for example, the commercially available scanners all have wide bores suitable for body scanning.

However, many centres have seen much if not all their neuroscience (and sometimes clinical neurological) imaging migrate towards simultaneous PET-MR scanners. The underlying reasons are practical (an MRI is virtually always required for research brain PET) and scientific (MR allows truly simultaneous assessment of physiological parameters like blood flow, EEG can be more easily integrated than for PET-CT). Methodological issues like appropriate attenuation correction have largely been addressed (1, 2), and new fields have been facilitated, e.g. MR-informed PET reconstruction (3). In the neurosciences, simultaneous PET-MR has enabled novel insights that would not previously have been possible to obtain in the same subject at the same time, for example the relationship between blood flow changes and receptor binding time-activity curves (4) and intercomparison between methods (5).

In cardioscience, PET-MR has obvious potential for motion correction which is starting to be exploited (e.g. 6). Novel fields include inflammation (brain, vessels, musculoskeletal).

Across all fields, machine learning supported by artificial intelligence is making inroads, particularly around the technical aspects (attenuation (2) and motion correction, ultra-low-dose imaging). It is to be expected that this will be extended to parametric mapping and clinical questions.

References:


Developments and Challenges in Theranostics
WHERE ARE WE WITH THERANOSTIC IMAGING TODAY?

LIOE-FEE DE GEUS-OEI (LEIDEN, NETHERLANDS)

Nuclear medicine thrives by continuous changes. The current decade a wave of new theranostic compounds, targeting the same receptor for imaging and therapy, will change the oncology therapeutic arsenal [1,2]. This CME session will review the current status of theranostics from a clinical perspective and identify key clinical needs to be addressed with future developments. The first part of this lecture deals with theranostic applications for radionuclide treatments. In nuclear medicine we have several applications, where we make use of the same set of molecules. The molecule can either be coupled to a SPECT or PET radionuclide, or to an α or β-emitter to perform radionuclide treatment (such as \(^{111}\)In-\(^{111}\)In-MIBG, \(^{90}\)Y- or \(^{166}\)Ho-microspheres, \(^{177}\)Lu-Dotatate, \(^{225}\)Ra, \(^{177}\)Lu-PSMA or \(^{225}\)Ac-PSMA etc) [3-5]. There are, however, also nuclear medicine theranostic applications for non-radionuclide treatments, which is addressed in the second part of this lecture (such as \(^{18}\)F-FES, \(^{89}\)Zr-trastuzumab, \(^{89}\)Zr-nivolumab, \(^{89}\)Zr-atezolizumab, \(^{89}\)Zr-bevacizumab, \(^{89}\)Zr-girentuximab etc) [6-8]. PET imaging with tumour specific tracers, has the potential to select the most suitable therapy for each individual patient. Up-front or early detection of non-responding patients might aid to select the right patients for the right drug at early time points. As a prerequisite for future successful clinical translation, properly designed randomized clinical trials need to be performed and phase 3 clinical trials exploiting target visualization with PET and individualized therapies will help to realize the full potential of clinical theranostics. The oncological treatment triangle currently consists of (1) surgery and other local treatments, (2) systemic treatments including chemo-, hormone-, targeted- and immunotherapy and (3) external beam radiation therapy. Radioligand therapy, however, also deserves a place in the oncological treatment triangle (which will become a quadrilateral). The time is ripe to work on a strategy how to roll out radioligand therapy in different national contexts and how to set up theranostic centers in Europe and beyond. What does the cancer community have to do to boost readiness for implementation of radioligand therapy in standard cancer care and to prepare the policy environment to be ready for this?

References:
The concept of radiotheranostics has been realized with $^{68}$Ga- and $^{177}$Lu-labeled tumor targeting agents for PET imaging and targeted radionuclide therapy, respectively. The success of the “matched pair” principle is undisputed, yet, in an ideal case, the diagnostic and therapeutic radiometal would have equal chemical properties resulting in chemically identical radiopharmaceuticals characterized by equal distribution profiles.

Among a variety of emerging radionuclides currently employed or proposed for radiotheragnostics, terbium has attracted the attention of the community, as it comprises four medically interesting radioisotopes (terbium sisters) for all four modalities in nuclear medicine (1). Terbium-152 and terbium-155 are the diagnostic radioisotopes with decay characteristics suitable for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, respectively. They may be particularly useful for dosimetry purposes to enable prospective therapy planning. Terbium-149 and terbium-161 are suitable for targeted α-therapy and for a combined β⁻ and Auger electron therapy, respectively (2,3).

Due to the chemical similarities to lutetium, terbium radioisotopes can be stably coordinated with a DOTA chelator. In preclinical studies, it was confirmed that the tissue distribution of a particular radiopharmaceutical remains the same irrespective of whether lutetium-177 or any of the terbium radioisotopes is employed (3). This situation opens new perspectives for various applications of the terbium sisters with existing tumor-targeting agents.

This CME lecture will shed light on the current stage of all four terbium sisters from production to preclinical research and first-in-man application (4,5). In particular, the opportunities and challenges of radiotheranostics based on the use of terbium radioisotopes will be discussed.

References:

QUANTITATIVE THERANOSTIC IMAGING - CHALLENGES AND OPPORTUNITIES

MARK KONIJNENBERG (ROTTERDAM, NETHERLANDS)

Dosimetry forms an integral part of theranostics, ideally a pre-therapeutic diagnostic scan will provide guidance on options for successful therapy and a prediction of the doses that can be safely achieved. In most cases pre-therapy PET diagnostic scans merely indicate specific uptake of the tracer in the volumes to be treated. The most commonly used PET radionuclides $^{18}$F and $^{68}$Ga cannot provide additional information on long-term retention of the radiopharmaceutical, essential for dosimetry estimates using longer-lived alpha- or beta-particle emitters. Specific activity may differ considerably between diagnostic and therapeutic applications leading to variance in the pharmacokinetics depending on the molar amounts of ligand administered. The most reliable theranostic imaging is provided by peri-therapeutic imaging; quantitative imaging at various time-points after the first cycle of therapy. Clinical examples in $^{177}$Lu-PSMA therapy will be presented on the options for peri-therapeutic dosimetry and the predictive value of single time-point PET imaging with $^{68}$Ga-PSMA.
Pregnancy and Breastfeeding in the Context of Nuclear Medicine
STATUS OF GUIDELINES ON BREASTFEEDING

SIGRID LEIDE-SVEGBORN (MÄLÖ, SWEDEN)

Administration of radiopharmaceuticals to mothers who are breastfeeding is generally avoided because the activity may be secreted into the breast milk, which results in unnecessary irradiation of the infants. Breastfeeding is very important for the infant as well as for the mother [1] and when a nuclear medicine procedure of a breastfeeding mother is of vital importance it may be necessary to temporarily interrupt breastfeeding. Unfortunately, it is often terminated even though it is not necessary. On the other hand, in situations when a necessary cessation is ignored, there is a risk of serious harm to the infant. Thus, it is important to have access to proper, clear, and easily accessible recommendations on the duration of an appropriate interruption.

Systematically collected data on the secretion of radionuclides into breast milk are rare [e.g. 2]. Data are often published in the form of case reports [e.g. 3] or as reviews [4, 5] based on compilation of data published earlier. Recommendations on breastfeeding of specific radiopharmaceuticals are given in the Summaries of Product Characteristics (SPC). These often recommend termination even though it is not necessary. More explicit guidelines on breastfeeding interruption are available via international radiation protection bodies, such as ICRP [6] and IAEA [7]. Their recommendations are similar but with some obvious differences. Most importantly, the recommendation to terminate breastfeeding after administration of radioiodide are consistent. A minor difference is the recommendation for most radiopharmaceuticals labelled with 99mTc; no interruption necessary (ICRP) or a possible four-hours’ interruption (IAEA). Another difference is that IAEA has subgroups of recommendations for some radiopharmaceuticals used for different indications with different activity levels. Since the recommendations of these two organisations were published, 2015 (ICRP) and 2018 (IAEA) new radiopharmaceuticals have been introduced and additional data on radionuclides in breast milk for previous substances, have been published. Also, the current recommendations from The European union, EU [8] need to be updated.

The contribution to the infant dose from external irradiation due to close contact with the mother is often insignificant compared to the dose due to ingestion but there are examples, 18F-FDG among others, where the external dose significantly exceeds the dose due to ingestion, which should be kept in mind when recommendations are given.

References:

THE PREGNANT PATIENT - RISKS FOR THE FETUS

François Jamar (Brussels, Belgium)

Administration of radiopharmaceuticals to pregnant women raises several problems, i.e., i) what is the risk for the foetus, ii) what recommendations can be made to mitigate them and iii) how should we communicate about this?

Risks to the foetus can be distributed into deterministic and stochastic risks. The first are related to relatively high doses, namely 50 or more mSv. This level of effective dose is never reached in nuclear medicine diagnostic procedures. It can be reached in nuclear therapies, which are strictly to be avoided in pregnant women, unless the benefit for both the mother and child-to-be is higher than the abstention of therapy, which is most unlikely. In all cases, the advice of the local ethic committee must be sought in such circumstances.

The risks for the embryo and foetus vary with time. In the very early stage of the pregnancy, after conception, the no/all effect applies, which means that there will be no consequence to the conceptus but alive or not. In the embryonic period, doses above 100 mSv may lead to congenital malformation by virtue of linear affect with a threshold. Effects on the foetal development or intellectual quotient (IQ) can also be expected (i.e., 30 points/gray).

Besides, the stochastic risks, for lower doses, may exist: they are based on the linear-non-threshold effect, which is the conservative way of dealing with low doses. Effective doses in diagnostic NM are in the range of 0.2 to 10 mSv, well below the threshold for deterministic effects. Doses to pregnant women are as such not relevant but are a rough method to estimate the dose to the foetus.

The most important issue is to identify the risk. When a nuclear medicine procedure is needed, an estimate of the exposure to the embryo/foetus should be available, and discussed with the patient, mainly in terms of stochastic risk, which is essentially a minimal increase in childhood cancer: it must be remembered here that this effect it totally independent of the time of pregnancy, being the same for instance at 12 or 36 weeks. There should be no issue about deterministic risks for diagnostic nuclear medicine, regardless of the tracers used nowadays.

Communication with the patient is essential with regards to i) the risk of pregnancy and its screening and ii) the risks in case of known pregnancy. Efforts should be dedicated to identifying the risk of pregnancy especially in the youngest and most vulnerable patients. Direct questioning is of utmost importance whenever possible.

References:
Administration of radiopharmaceuticals to pregnant and breastfeeding women is generally avoided. Exceptional cases that include the administration during unknown pregnancy or the priority for the mothers’ health, require the evaluation of absorbed doses to the foetus or the nursing infant. Radiation dose estimates to the foetus or the infant offer information that can guide decisions and alleviate psychological stress. Two main scenarios can be considered: i) specific data collection can be planned for personalized dosimetry; ii) only the amount of injected activity (and/or imaging) is available. Accordingly, specific dosimetry methods can be applied depending on the radiopharmaceutical, or dosimetry can be extrapolated from available biokinetic models, phantoms, population data, and/or software tools. The absorbed dose to the uterus may be a substitute for the absorbed dose to the embryo in the first 2-3 months of pregnancy. For radioactive substances with placental transfer, the absorbed doses to organs of the mother may be taken as representative of those to the foetus organs. Some authors provided more detailed radiation dose estimates for the foetus at various stages of pregnancy, and other studies evaluated the biokinetics and dosimetry to infants by analysing radioactivity concentrations in the breast milk and the effective half-life. These kinds of data are available for several radiopharmaceuticals. Some dosimetry software incorporates phantoms of pregnant women.

This presentation will overview the practical methods to estimate radiation doses to the unborn baby, pregnant/nursing mother, and infant during breastfeeding. Examples will be provided considering most common radiopharmaceuticals for PET, cardiac, and pulmonary diagnostic examinations, sentinel lymph node for breast surgery, and treatment for thyroid cancer. Considering situations i) and ii), the data required for dose estimates will be highlighted, models and/or dosimetry data available from the literature indicated, and sources of uncertainty highlighted.

References:


Back to the Future - New Kit-Based Approaches for Labelling Radiopharmaceuticals ($^{68}$Ga, $\text{Al}[^{18}\text{F}]$, ...)

LABELING COLD KIT WITH $^{68}$Ga - THE FUTURE IS BRIGHT

Clément Morgat (Bordeaux, France)

The availability of radiopharmaceuticals for molecular imaging is critical to improve patient care. To disseminate radiopharmaceuticals, ready-to-use lyophilized kits are prerequisites for the rapid and reproducible preparation of radiopharmaceuticals while avoiding the need for complex syntheses and formulations using automated synthesizers [1]. $^{99m}$Tc-kits for SPECT imaging illustrate well the potential of standardized preparations of radiopharmaceuticals. In PET, $^{68}$Ga has deeply modified our practices in PET radiopharmacy during the last decade and similar achievements of kit-based formulation of $^{68}$Ga-radiopharmaceuticals are expected with current clinical applications in neuroendocrine tumors patients and prostate cancer patients. $^{68}$Ga-kits are unique because of the acidic behavior of the gallium ion which requires strong electron donors provided by (un)specific chelators associated with the biomolecule [2]. $^{68}$Ga is available through marketed $^{68}$Ge/$^{68}$Ga generators which provide gallium 3+ ion in different reactional volume making radiolabeling standardization challenging. Recently, $^{68}$Ga production was also reported to be feasible in cyclotron and high activities up to several gigabecquerels have been obtained [3] questioning the systematic use of scavengers in $^{68}$Ga-kits [4]. Finally, the discovery of novel targets on tumors cells and the increasing availability of the corresponding $^{68}$Ga-radiopharmaceuticals decorated with various chelate, would increase the number of cold kits available in clinics for PET imaging. Therefore, in this CME dedicated to labeling cold kits with $^{68}$Ga, aspects of development with respects to chelators, cold kit composition, radiolabeling procedures and present and future clinical applications will be discussed.

References:

AL$^{18}$F$^-$
FROM MODULES TOWARD A KIT-BASED RADIOFLUORINATION?

CHIARA DA PIEVE (LONDON, UNITED KINGDOM)

Because of its high positron emission (97%), low positron energy ($\beta^+_{\max} = 0.64$ MeV) and its half-life (108.9 min), fluorine-18 is often considered the "ideal" PET radioisotope. Generally, the incorporation of fluorine-18 into molecules is achieved through the formation of a carbon-fluorine bond. This process is usually designed uniquely for each new molecule, requires $^{18}$F drying, multiple steps, high temperatures (>100°C) and the use of anhydrous organic solvents. Unfortunately, these conditions are unsuitable for molecules such as peptides and proteins. In 2009, McBride et al. reported a one-pot direct radiofluorination (in aqueous medium) of biomolecules with the Al$^{18}$F moiety based on the formation of the very strong bond between $^{18}$F and aluminium 1. Briefly, a solution of aluminium chloride in a pH 4 buffer is mixed with an aqueous solution of $^{18}$F and an organic co-solvent. This is then added to the chelator-biomolecule ensemble and incubated for 15 min 1. Importantly, this novel radiolabelling protocol does not affect the biological properties of the biomolecule. The choice of chelator is essential for the preparation of stable (i.e. no defluorination) Al$^{18}$F$^-$ labelled products in physiological conditions. To date, the most stable Al$^{18}$F$^-$ labelled molecules contain cyclic chelators such as NOTA or NODA. However, acyclic chelators (e.g. HBED and RESCA) have been recently investigated and showed encouraging results and applicability especially for thermosensitive biomolecules 2. The rapid (25-45 min) and straightforward Al$^{18}$F approach has since been used for an increasing number of peptides/ small proteins (e.g. RGD, PSMA, affibody molecules) and also small molecules such as clickable tags and inhibitors (e.g. folate, FAP1) 3,4. With clinical applications in mind, a lyophilized kit, prepared and reported by McBride et al., showed great potential and versatility for the preparation of Al$^{18}$F$^-$ labelled peptides 4. Additionally, several automated procedures have been developed on a variety of modules (e.g. Trasis AiO, GE TRACERlab) which are usually implemented in the production of small molecule-based $^{18}$F-tracers (e.g. FDG) 2,5. As a matter of fact, the one-pot procedure for direct $^{18}$F-labelling of biomolecules shows great compatibility with either cassettes or lyophilized cold kit formulations (e.g. a vial containing the biomolecule, aluminium chloride, bulking agent, buffer components, similar to the ones used for the GMPc preparation of $^{99m}$Tc and $^{68}$Ga radiopharmaceuticals). Importantly, with their pros and cons, both the cold kit and the automated module approaches represent an important and strong argument in favour of the clinical translation of the convenient Al$^{18}$F$^-$ radiofluorination technique.

References:
REGULATORY ASPECTS OF COLD KIT-BASED RADIOPHARMACEUTICALS IN THE EU

OLIVER NEELS (DRESDEN, GERMANY)

Kit-based radiopharmaceuticals, in particular those bearing $^{99m}$Tc as radionuclide, played and are playing a pivotal role in Nuclear Medicine in Europe over the last decades. Kits are also described in the EU directive 2001/83 on the Community code relating to medicinal products for human use [1]. Many approaches have been made to prepare kits for radiolabeling with other radionuclides [2-9], but so far only one kit for radiolabeling with $^{68}$Ga has received marketing authorization in Europe, namely SomaKit TOC [10], despite the fact that theranostic radiopharmaceuticals are on the rise. Do these promising methods fit into the current legislation or do we need change?

References:

10. European Medicines Agency (EMA). European public assessment report (EPAR) for SomaKit TOC.
Radionuclide Therapies - Management of Side Effects and Complications
Differentiated thyroid carcinoma (DTC) is a malignancy with increasing incidence and a favorable prognosis. Thus, there is growing concern about long-term side effects of DTC treatment, most notably radioactive iodine (RAI) therapy, but results of previous studies are conflicting and cohorts appear heterogenic. Side effects of RAI treatment may include nausea and vomiting, radiation thyroiditis and in rare cases sialadenitis and xerostomia, bone marrow suppression, gonadal dysfunction, second primary malignancies (SPM) and pulmonary fibrosis in presence of widespread pulmonary disease. As long-term adverse effects are a substantial part of patient-relevant outcomes, any risk-benefit-ratio has to consider the risk of SPM occurrence. Regarding the latter, the impact of RAI is the subject of an ongoing debate and the existing evidence is conflicting. The limitations concerning any kind of synthesis of results originate from lacking comparability between the studies. The cohorts may present a vast heterogeneity in itself and between each other based on exposure to lifestyle-factors and carcinogens, ethnicity or different screening practice. These confounders are not routinely recorded in most studies. Additionally, it is crucial to include appropriate control groups.

References:

Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment option for patients with metastatic, unresectable, progressive, somatostatin receptor (SSTR)-positive Gastroenteropancreatic-Neuroendocrine Tumours (GEP-NETs) and is recommended in clinical practice guidelines. Patients with NETs demonstrating adequate tumoral uptake on radionuclide somatostatin receptor imaging are eligible for PRRT. PRRT agents act via a ‘Trojan horse’ mechanism to enter and destroy NET cells. Currently, the most widely used PRRT is 177 Lu-DOTATATE. Other developed PRRT agents include 90-Y in complex with either DOTATATE or DOTATOC and other 177-Lu labeled ligands (DOTATOC or DOTANOC). Monitoring of acute and delayed side effects and complications is of paramount importance. Patients should be monitored during, in-between, and after PRRT treatment cycles. This presentation will discuss the evidence-based management of side effects and complications, and related challenges. Side effects of PRRT are usually mild, and the most commonly reported adverse events include nausea and vomiting, diarrhea, fatigue/asthenia, and musculoskeletal pain, which are mostly mild or moderate in intensity. Most nausea and vomiting cases are often related to amino acid administration and usually resolve after completing the infusion. In general, these can be prevented by avoiding electrolyte imbalances and ensuring adequate hydration. Irradiation of the hematopoietic tissue can lead to dose-limiting myelosuppression, manifesting clinically as anemia, lymphopenia, neutropenia, and/or thrombocytopenia, which may occur in isolation. PRRT might exacerbate the syndromes related to the respective functional tumors due to the sudden massive release of the hormones and receptor stimulation. Vital signs such as blood pressure and pulse should be monitored before and after PRRT, especially in symptomatic patients. Therapeutic interventions should be undertaken to treat the functional syndrome effects or exacerbation. The kidneys are the dose-limiting organs, and adequate kidney protection is mandatory.

References:
Castration-resistant prostate cancer (CRPC) treatment is an evolving challenge. Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) with either the beta-particle-emitting radionuclide lutetium-177 ($^{177}$Lu) or the alpha-emitting radionuclide actinium-225 ($^{225}$Ac) are promising new therapeutic approaches, however, the knowledge of side effects/toxicities is crucial. The results of a recently published meta-analysis including 1192 patients showed that approximately 46% of CRPC patients being treated with $>$1 cycle of $^{177}$Lu-PSMA PRLT have PSA reductions of ≥50% (1). In their meta-analysis, the pooled estimated proportion of patients with grade 3 or 4 adverse events for all evaluated toxicities was <10%. Here, the estimated proportions ranged from 0.01 for nausea, fatigue, diarrhea, and elevated aspartate transaminase to 0.08 for the highest reported complication anemia. Thus, the relatively high number of PSA responders alongside the low rate of toxicity reflects the potentially promising role of PRLT in treating CRPC.

Further, the recently published prospective, multicenter, randomized Phase II trial (TheraP) reported a significantly higher treatment response and less toxicity in patients receiving Lu-PSMA-617 versus cabazitaxel (2). However, some patients may not respond to $^{177}$Lu-PSMA-PRLT or the antitumor effect of $^{177}$Lu-PSMA PRLT can decrease over time. Such patients may respond to an alpha particle-emitting PRLT characterized by high linear energy transfer and short travel distances which may cause potent and local cytotoxicity to PSMA-expressing tumor cells (3). A recently published analysis evaluating Ac-225-PSMA-617 showed measurable antitumor effect after Lu-177-PSMA failure in late-stage mCRPC (4). However, grade 3/4 hematological side effects were observed in up to one-third of patients (anemia 35%, leucopenia 27%, and thrombocytopenia 19%) while all patients experienced grade 1/2 xerostomia leading to toxicity-associated treatment discontinuation in a relevant number of patients. Thus, theranostic agents in CRPC have to be selected carefully.

References:

New Concepts for Imaging and Therapy of Bone Metastases
NUCLEAR IMAGING OF BONE METASTASES

HELLE D. ZACHO (AALBORG, DENMARK)

For more than five decades bone scintigraphy with $^{99}$Tc-labelled bisphosphonates has been the preferred imaging modality for the evaluation of metastases in the skeletal system. The clinical value has been greatest in cancer types with osteoblastic metastases as seen in patients with prostate cancer and patients with breast cancer. Bone scintigraphy has been used for all stages of prostate cancer from primary staging, over recurrent disease to response assessment during therapy. Bone scintigraphy has proven to be a robust method with an adequate diagnostic accuracy, it is cheap and widely available.

Technical advancements in camera technique with the addition of SPECT/CT and PET/CT to the diagnostic armamentarium combined with the introduction of new and disease specific tracers have changed the landscape of nuclear imaging of bone metastases.

In prostate cancer, specific tracers such as choline, $^{18}$F-Fluciclovine (FACBC) and particularly prostate-specific membrane antigen (PSMA) have increased the diagnostic accuracy significantly for the detection of bone metastases and the tracers have gained widespread clinical use. In breast cancer the estrogen-receptor-tracer (FES) has shown very promising diagnostic properties. Moreover, common PET-tracers such as $^{18}$F-FDG and $^{18}$F-Sodium-fluoride (NaF) can be used for the assessment of bone metastases in numerous types of cancer. Most of the PET-tracers possess the inherent advantage of evaluating not only the skeletal system but also the extend of the primary tumor, lymph node metastases and soft tissue metastases.

References:

RADIONUCLIDE THERAPY OF BONE METASTASES

A. AFSHAR-OROMIEH (BERN, SWITZERLAND)

Various malignant diseases can give rise to bone metastases, for which the most relevant accompanying symptoms are pain, fractures, and bone marrow suppression. Radionuclide therapy is a useful palliative option among other treatments for bone metastases. Since metastatic malignant diseases are usually incurable, radionuclide therapy for bone metastases aims at pain reduction, delaying disease progression, and reducing complications such as pathologic fractures.

Radionuclide therapy uses bone seeking radiopharmaceuticals. Their accumulation in metastases has an association with increased skeletal metabolic activity, also described as osteoblastic activity and calcification. A baseline bone scan with $[^{99m}Tc]$-labeled bisphosphonates prior to therapy is mandatory to substantiate increased skeletal metabolic activity. Lytic bone metastases are not treatable by radionuclide therapy since they do not show increased skeletal metabolic activity.

Charles Pecher introduced strontium-89 ($^{89}$Sr) in 1939 as the first application of bone-seeking radiopharmaceuticals in medical therapy procedures. $^{89}$Sr is a beta-emitting radionuclide that substitutes for calcium for incorporation into the bone matrix. In Europe, $[^{89}S$r]-chloride is approved for use in patients with bone metastases of prostate cancer, whereas samarium $^{153}$Sm (another beta-emitter) bound to the bisphosphonate EDTMP is approved for the treatment of pain from osteoblastic bone metastases of any type of malignant diseases.

During the last two decades, the demand of radionuclide therapy with bone-seeking beta-emitters has declined due to improvements in cancer and pain treatment as well as other factors. In addition, the alpha-emitter Xofigo ($^{223}$Radium-dichloride) was clinically introduced as an alternative for treatment of symptomatic metastatic castration resistant prostate cancer (mCRPC), following upon its approval in 2013 by the EMA and FDA. Xofigo is another calcium mimic, which also selectively binds to zones of increased bone turnover in bone metastases. In a phase-3 clinical trial, Xofigo significantly improved overall survival of men with mCRPC and bone metastases when compared to placebo (median OS 14.0 months vs. 11.2 months). In 2018, the EMA placed certain restrictions on the use of this therapeutic agent, namely that it must not be used in conjunction with Zytiga (abiraterone acetate) or the corticosteroids prednisone or prednisolone, since these combinations increased the risk of earlier death or bone fractures as compared to placebo treatment.

Since 2011, radioligand therapy with PSMA-ligands is available for patients with mCRPC. In contrast to bone-seeking radiopharmaceuticals, PSMA-ligands (labelled with beta- or alpha-emitters) seek all metastases that have elevated PSMA-expression, irrespective of their location (bone, lymph nodes, organs, etc.). Although there has been no direct comparison between Xofigo and PSMA-radioligand therapy, several retrospective studies suggest that PSMA-radioligand therapy can be more effective.
ABLATIVE IRRADIATION OF BONE METASTASES

PIET DIRIX (ANTWERP, BELGIUM)

Radiation therapy (RT) is an established treatment for painful and/or complicated bone metastases. The goal is to ease or prevent debilitating symptoms such as pain, fractures, and spinal cord compression. Usually, a single fraction of 8.0 Gy is delivered, as no other fractionation schedule is superior regarding pain relief, preservation of function, or maintenance of skeletal integrity [1, 2]. Typically, such palliative RT is delivered with conventional techniques, broadly encompassing the intended target volume. Over the last decades, RT delivery has improved considerably through the use of intensity-modulation (IMRT) as well as image-guidance (IGRT). These innovations have resulted in the introduction of stereotactic body radiation therapy (SBRT), delivering very high doses in a limited number of fractions in a highly conformal manner. In principle, SBRT allows for the “ablation”, i.e. total eradication of all disease, of bone metastases, with few side-effects.

SBRT for bone metastases has been initially tested in oligometastatic disease (OMD). Considerable evidence shows that SBRT for OMD is safe with acceptable toxicity, as well as efficient with high rates of local control [3-6]. Because of the clear success of SBRT in OMD, it seems reasonable to also investigate this technique in a more palliative setting. The highly conformal delivery of SBRT is expected to result in an improved acute toxicity profile. Moreover, it is now possible to deliver significantly escalated doses to the metastases, potentially resulting in higher symptomatic efficacy and less re-irradiation need. The results so far have been mixed, and several randomized controlled trials are still recruiting [7, 8].

References:

Nuclear Medicine in the Evaluation of Child Abuse
CLINICAL ASPECTS OF CHILD ABUSE

REFERS TO CME TALK: CHILD ABUSE CLINICAL FEATURES, DIAGNOSIS AND MANAGEMENT

HADAS YECHIAM (KFAR SABA, ISRAEL)

Child abuse and neglect (CAN) includes all types of physical and/or emotional ill-treatment, sexual abuse, neglect, negligence, and commercial or other exploitation, which results in actual or potential harm to the child’s health, survival, development or dignity in the context of a relationship of responsibility, trust or power.

The incidence of CAN, when evaluated directly from the children, is close to 20%.

In many countries reporting on child abuse to child protective services is mandatory. In some for all citizens and in some only for designated personnel (such as healthcare or education).

Risk factors relate to the community, the parents and the child.

The manifestations of physical abuse are most likely to involve skin injuries, followed by bone fractures and head trauma. The identification of physical abuse can be difficult. It is important to be aware of red flags in the clinical history, the physical exam and the behavior of the child and parents/caretakers.

The workup in cases of suspected CAN includes comprehensive history taking, performing a meticulous physical exam, evaluation by a social worker and ancillary testing. The ancillary tests usually include imaging and laboratory tests to support the suspicion of abuse and to rule out alternative diagnoses.

In cases where there is concern for the safety of a child in his home there is need to implement a protection plan, either by hospitalizing the child or by finding an alternative safe environment, with the help of the child protective services.

References:

1. WHO. https://www.who.int/news-room/fact-sheets/detail/child-maltreatment
NUCLEAR MEDICINE IN THE EVALUATION OF CHILD ABUSE

Laura Drubach (Boston, United States of America)

Child abuse is a social problem that requires a multidisciplinary approach. Bone fractures are often encountered in cases of child abuse, being second in incidence only to soft tissue injuries. Skeletal injuries are present in approximately 55% of children that are physically abused (1). Nuclear Medicine imaging plays an important role in the detection and characterization of skeletal fractures.

In a study performed by Kemp et al. in 2008 it was found that rib fractures had the highest probability for abuse. (71% of cases) (2). Long bone fractures had a lower incidence than rib fractures but were also common, with humeral fracture 48% of cases and femoral fractures 28%. The probability for skull fractures was 30%, being most commonly a linear fracture. Certain types of fractures, because of the mechanism of injury needed to produce them, are known for the high specificity to be secondary to child abuse. Some other fractures are commonly seen in accidental injuries and do not raise the suspicion for child abuse (3).

According to the American Academy of Pediatrics and the American College of Radiology, the imaging method of choice for evaluation of fractures of children younger than 2 years at the time of presentation is the skeletal survey (4).

Nuclear Medicine imaging has a complementary role due to the high sensitivity for detection of fractures in infants being evaluated for child abuse, especially for the detection of rib fractures. This is of particular importance since these are the most common fractures found in child abuse (5).

References:

RADIOLOGICAL ASPECTS OF CHILD ABUSE

CHIARA GIRAUDO (PADUA, ITALY)

It is well known that radiological imaging can significantly contribute to the diagnostic process and investigation in cases of non-accidental pediatric traumas and this lecture will provide a comprehensive overview of the role and appropriateness of different radiological techniques including x-ray, CT, and MRI in this field. In particular, the main characteristics of fractures at skeletal survey, the application of CT for head and visceral injuries as well as the use of MR and WBMRI will be reviewed.

Lastly, the application of advanced imaging techniques like machine learning and artificial intelligence for the detection of fractures and their potential use in children victims of abuse will also be addressed.

References:
5. Li-Chun Hsieh et al. Revisiting Neuroimaging of Abusive Head Trauma in Infants and Young Children. AJR 2015;204:944-952.
Immunotheranostics
Immune checkpoint inhibitors have substantially changed the field of oncology over the past few years. Immune checkpoint inhibitors offer an alternative treatment strategy by exploiting the patients’ immune system, resulting in a T cell-mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients does not respond to Immune checkpoint inhibitors. Molecular imaging, using positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this session, recent advances in PET imaging of immune checkpoints and immune cells will be presented. These studies are, until now, mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of immune checkpoint inhibitor therapy.

References:

COMBINING IMMUNOTHERAPY AND RADIATION - IS THE WHOLE MORE THAN THE SUM OF ITS PARTS?

FERNANDA HERRERA (LAUSANNE, SWITZERLAND)

The discovery of new methods for inflaming tumors is critical for increasing immunotherapy response. (1-3)

We found that low-dose radiation reprogrammed the tumor microenvironment of advanced murine ovarian tumors with low immune infiltration and, when combined with immunotherapy, induced simultaneous mobilization of innate and adaptive immunity, primarily via effector T cells, to achieve tumor control. Treatment efficacy was dependent on new states of CD4, CD8, as well as dentritic cells discovered by single cell RNA sequencing. The benefit of low dose irradiation to all metastatic deposits in combination with immunotherapy was seen in patients with metastatic immune-cold tumors.

High doses of fractionated whole abdominal irradiation were used in the past as an effective postsurgical adjuvant therapy in the management of ovarian cancer, however, fell out of favor due to its high toxicity to the intestine and inability to be combined with chemotherapy. (4) According to our findings, lower doses of whole abdominal irradiation should be further investigated in conjunction with immunotherapy in order to increase immune infiltration in otherwise cold-insensitive tumors. (4)

References:


NUCLEAR MEDICINE IMMUNOTHERANOSTICS - SYNERGISMS AND ANTAGONISMS

NIKLAUS SCHAEFER (LAUSANNE, SWITZERLAND)

Nuclear Medicine immunotheranostics means to visualize, modulate or eradicate barriers against anti-cancer immunotherapies by nuclear medicine theranostic techniques (1). To understand how to implement Nuclear Medicine immunotheranostics successfully from research trials to clinical routine we have to understand its antagonisms and synergisms a) in a biological and mechanistic sense, b) in the sense of how to design the most useful clinical trials and c) at the level of the physicians’ interactions in both intrinsically interacting fields, Nuclear Medicine and Medical Oncology. First, on the level of cancer biology and immunology, we have to understand antagonism and synergism of the different treatment strategies on a molecular, biological level (2). Here, our classical theranostic concept “search the target - eliminate the target” needs to be put into context of the constantly changing and highly complex tumor microenvironment. Second, at the level of clinical trial design we have to address the problem of who would support large randomized trials, i.e. if and where academia and pharmaceutical industry can synergize, and what could be antagonistic forces for having such trials (3). We have also to think of ethical problems like how to cope with patients having inconsistent results in imaging and biopsy or how to design endpoints to be able to convince e.g. health economists of expensive diagnostic methods such as molecular imaging (4). Third, “synergism and antagonism” also touches on how nuclear medicine specialists and oncologists collaborate. It is therefore of utmost importance to invest in an efficient training at the interface of - especially our younger - nuclear medicine specialists with medical oncologists. Only if we address all of the above three dimensions we will implement Nuclear Medicine Theranostics successfully in the future for the good of our patients.

References:

Probing Tumour Metabolism - An Update
Targeting oncogene drivers is one of the most promising treatment strategies in oncology and several targeted agents are currently approved or are under clinical development for therapy. The inhibition of oncogene drivers is usually followed by growth arrest and apoptosis causing tumor regression. However, in response to a prolonged inhibition of oncogene drivers, cancer cells may become resistant due to target mutations or adoption of compensatory pathways that maintain the mitogenic cascade as persistently activated. Imaging of proliferation by radiolabeled nucleosides may provide an early detection of sensitivity and resistance of cancer cells to inhibitors of oncogene drivers allowing the selection of patients for targeted therapy and evaluation of drug effects. Furthermore, the ability of new agents to inhibit oncogene drivers may be tested by imaging of proliferation in animal models thus promoting their moving from laboratory to clinical settings.

EGFR is a well-recognized oncogene driver of non-small cell lung carcinoma (NSCLC) and has been considered as a paradigm of targeted therapy in cancer. Animals bearing sensitive tumors subjected to PET/CT with 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) showed a marked reduction of 18F-FLT uptake early after treatment with EGFR tyrosine kinase inhibitors (TKIs). Conversely, refractory tumors showed an unchanged or even increased tracer uptake at the same time points. Moreover, treatment with agents capable of reversing the specific mechanism of resistance caused a significant decrease of 18F-FLT uptake in resistant tumors as compared to baseline scan thus indicating treatment efficacy. In order to prevent or overcome resistance, current strategies of targeted therapy includes the rational combination of selective inhibitors of oncogene driver and adaptive pathways. Monitoring tumor response to combined therapy using 18F-FLT PET/CT allowed us to detect and quantify the enhanced effects of two inhibitors as compared to single agent treatment on proliferation.

These results are clinically relevant since no other non-invasive imaging method allows the early detection of drug synergy in vivo. The present talk will focus on the role of imaging with radiolabelled nucleosides in all clinically relevant steps of targeted therapies including patient selection, early monitoring of drug effects, reversal of drug resistance and dual target inhibition.

References:

ILLUMINATING METABOLIC HETEROGENEITY AND VULNERABILITIES IN LUNG CANCER

♦ DAVID LEWIS (GLASGOW, UNITED KINGDOM)

Tumour heterogeneity contributes intrinsic drug resistance leading to treatment failure and poor outcomes in lung cancer [1]. We have developed imaging approaches to dynamically identify regional metabolic heterogeneity and used these signatures to guide spatial molecular profiling and target local vulnerabilities.

To evaluate metabolic heterogeneity we have developed several radionuclide multiplexed technologies with radiolabelled probes $^{18}$F-FDG and $^{1-11C/14C}$acetate in the “humanised” Kras$^{G12D/+}$p53$^{-/-}$ genetically engineered mouse model of lung cancer [2, 3]. We non-invasively identified two spatially heterogeneous metabolic subtypes, one with high $^{18}$F-FDG and the other with high [1-11C] acetate uptake. Molecular profiling of these two imaging phenotypes showed distinct transcriptional, proteomic and metabolic profiles. Regions of lung adenocarcinoma with higher glucose consumption are more proliferative, with activation of cell cycle genes, Myc targets and unfolded protein response. While regions of high acetate consumption have signatures for fatty acid metabolism, reactive oxygen species, TCA cycle and oxidative phosphorylation. Isotopologue tracing with [U $^{13}$C]glucose and [U-$^{13}$C] revealed that FDG-avid tumours utilise glucose for synthesis of serine and glycine while using acetate to replenish the TCA cycle. In contrast, acetate-avid tumours use glucose for TCA anaplerosis, amino acid biosynthesis, and acetate for fatty acid synthesis.

We went on to determine if these phenotypes have distinct vulnerabilities by targeting fatty acid synthase (FASN) using a novel inhibitor (GSK2194069) [4]. FASN inhibition is currently under investigation for efficacy in a subset of patients with oncogenic KRAS driven lung cancer (NCT03808558) [5]. Our results show that using [1-11C]acetate PET imaging can both identify and measure response in lung tumours dependant on the fatty acid synthesis pathway.

Metabolic imaging can identify distinct cancer phenotypes with different biology and response to treatment suggesting that metabolic imaging could guide treatment of heterogeneous tumours in lung cancer.

References:

IMAGING TUMOUR METABOLISM AND ITS HETEROGENEITY WITH MRI

FERDIA GALLAGHER (CAMBRIDGE, UNITED KINGDOM)

There is increasing evidence to support the role of metabolism in tumour development: deregulation of cellular energetics is a key hallmark of cancer. Changes in this metabolism have been shown to be early biomarkers of successful response to both chemotherapy and radiotherapy. This talk will focus on the role of MR in probing tumour metabolism.

Proton MR spectroscopy (1H-MRS) has been used to detect oncometabolites - or metabolites that promote cancer formation - which are present in some tumours due to mutations in mitochondrial enzymes. For example, 1H-MRS can be used to detect fumarate and succinate secondary to mutations in the enzymes fumarate hydratase and succinate dehydrogenase respectively. These mutations are found in a range of tumours including renal cell carcinoma, gastrointestinal stromal tumours and paragangliomas. We have shown that fumarate levels may change over time with treatment as a biomarker of response.

Hyperpolarized carbon-13 MRI (13C-MRI) is an emerging molecular imaging method for studying cellular metabolism. This technique allows non-invasive measurements of tissue metabolism in real-time. To date, the most promising probe used in conjunction with hyperpolarized MRI has been 13C-labelled pyruvate: pyruvate is metabolized into lactate in normal tissue in the absence of oxygen, but in tumours this occurs very rapidly even in the presence of oxygen. Results from many animal models have shown that there is a reduction in the metabolism of pyruvate following successful treatment with chemotherapy. Tumour lactate labelling has also been shown to correlate with the grade of some tumour types such as breast and prostate cancer and can be used to monitor treatment response.

Imaging methods to probe tumour metabolism could play an important role in stratifying tumours and detecting response to therapy.

References: